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Mutations in the NHEJ Component XRCC4
Cause Primordial Dwarfism
Jennie E. Murray,1,13 Mirjam van der Burg,2,13 Hanna IJspeert,2 Paula Carroll,1 Qian Wu,3
Takashi Ochi,3 Andrea Leitch,1 Edward S. Miller,4 Boris Kysela,5 Alireza Jawad,2 Armand Bottani,6
Francesco Brancati,7 Marco Cappa,8 Valerie Cormier-Daire,9 Charu Deshpande,10 Eissa A. Faqeih,11
Gail E. Graham,12 Emmanuelle Ranza,6 Tom L. Blundell,3 Andrew P. Jackson,1,* Grant S. Stewart,4,*
and Louise S. Bicknell1
Non-homologous end joining (NHEJ) is a key cellular process ensuring genome integrity. Mutations in several components of the NHEJ
pathway have been identified, often associated with severe combined immunodeficiency (SCID), consistent with the requirement for
NHEJ during V(D)J recombination to ensure diversity of the adaptive immune system. In contrast, we have recently found that biallelic
mutations in LIG4 are a common cause of microcephalic primordial dwarfism (MPD), a phenotype characterized by prenatal-onset
extreme global growth failure. Here we provide definitive molecular genetic evidence supported by biochemical, cellular, and immuno-
logical data for mutations in XRCC4, encoding the obligate binding partner of LIG4, causing MPD. We report the identification of
biallelic mutations in XRCC4 in five families. Biochemical and cellular studies demonstrate that these alterations substantially decrease
XRCC4 protein levels leading to reduced cellular ligase IV activity. Consequently, NHEJ-dependent repair of ionizing-radiation-induced
DNA double-strand breaks is compromised in XRCC4 cells. Similarly, immunoglobulin junctional diversification is impaired in cells.
However, immunoglobulin levels are normal, and individuals lack overt signs of immunodeficiency. Additionally, in contrast to individ-
uals with LIG4 mutations, pancytopenia leading to bone marrow failure has not been observed. Hence, alterations that alter different
NHEJ proteins give rise to a phenotypic spectrum, from SCID to extreme growth failure, with deficiencies in certain key components
of this repair pathway predominantly exhibiting growth deficits, reflecting differential developmental requirements for NHEJ proteins
to support growth and immune maturation.Introduction
Microcephalic primordial dwarfism (MPD) encompasses a
heterogeneous group of disorders, all characterized by
extreme global growth failure. The cardinal features of
MPD are in utero and postnatal growth retardation with
significant microcephaly, with height and occipitofrontal
circumference (OFC) at least 4 SD below the mean.1,2
Clinically recognizable forms of MPD include MOPD I
(MIM 210710) caused by mutations in the U12 minor
spliceosomal component, RNU4ATAC (MIM 601428);3,4
MOPD II (MIM 210720) due to mutations in PCNT (MIM
605925), encoding the centrosomal scaffold protein,
pericentrin;5,6 and defects in multiple components of
the pre-replication complex resulting in Meier-Gorlin
syndrome (MIM 224690, 613800, 613802, 613803,
613804).7–9 A number of important DNA damage response
genes have also been implicated in MPD, including ATR
(MIM 601215), ATRIP (MIM 606605), and RBBP8 (encod-
ing CtIP) (MIM 604124),10–12 which are associated with
Seckel syndrome. However, it is still difficult to clinically1MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Med
Immunology, Erasmus MC, University Medical Center Rotterdam, 3015 Rotte
bridge, Cambridge CB2 1GA, UK; 4School of Cancer Sciences, University of Bir
Medicine, University of Birmingham, Birmingham B15 2TT, UK; 6Departm
Switzerland; 7Department of Medical, Oral and Biotechnological Sciences,
8Endocrinology and Diabetes Unit, IRCCS Bambino Gesu` Children’s Hospital, 0
Paris Descartes-Sorbonne Paris Cite´, Institut Imagine, Hoˆpital Necker Enfan
10Department of Genetics, Guy’s Hospital, Guy’s and St Thomas’ NHS Foundat
Medical City, Riyadh 11525, Saudi Arabia; 12Department of Genetics, Childre
13These authors contributed equally to this work
*Correspondence: andrew.jackson@igmm.ed.ac.uk (A.P.J.), g.s.stewart@bham.a
http://dx.doi.org/10.1016/j.ajhg.2015.01.013. 2015 by The American Societ
412 The American Journal of Human Genetics 96, 412–424, March 5categorize many individuals with MPD based solely on
phenotype, with a syndromic diagnosis often not possible.
A gene-based classification for diagnosis and subsequent
management would be desirable, although at present this
is not possible for a significant proportion of individuals
for whom the molecular basis of their MPD has yet to be
established.
Recently, we and others identified biallelic truncating
mutations in LIG4 (MIM 601837), which encodes the
principal ligase involved in non-homologous end joining
(NHEJ)-mediated DNA repair, in a large number of MPD-
affected individuals13,14 and also two Dubowitz-affected
siblings,15 establishing this as the second most common
cause of MPD after PCNT mutations. LIG4 deficiency
(MIM 606593) had previously been described for a range
of phenotypes including severe combined immuno-
deficiency (SCID), microcephaly, and isolated radiation
hypersensitivity/malignancy predisposition.13,16–22
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breaks (DSBs). Free DNA ends are rapidly bound by the
Ku70-Ku80 heterodimer, which recruits and activates
DNA-PKCS and Artemis, the latter of which is required to
cleave damaged DNA overhangs prior to infilling by poly-
merases m and l. Finally, ligation is performed by the
XRCC4-XLF-LIG4 complex. XRCC4 and XLF are thought
to act in concert to form a filament that wraps around
the DNA ends, bridging the gap and acting as a stabilizer
for LIG4 to complete ligation.25 In addition to repairing
spontaneous and ionizing-radiation-induced breaks, the
NHEJ pathway plays an essential role in V(D)J recombina-
tion to ensure a diverse repertoire of T and B cells.26 After
the cleavage of DNA at the recombination signal sites by
RAG1 and RAG2, the NHEJ components stabilize the free
DNA ends and permit random deletion of nucleotides by
nucleases and random insertion of non-templated nucleo-
tides by terminal deoxytransferase (TdT), before final liga-
tion by XRCC4-XLF-LIG4.
Mutations have been described in many components
of the NHEJ pathway,27 including DCLRE1C (encoding
Artemis [MIM 605988]),27 PRKDC (encoding DNA-PKCS
[MIM 600899]),28 and NHEJ1 (encoding XLF [MIM
611290]),29–31 associated with SCID with or without asso-
ciated microcephaly and variable stature. Given the associ-
ation of LIG4 with MPD, XRCC4 (MIM 194363) was also
recently suggested as a candidate gene in which amutation
might cause MPD,32 after identification of a rare missense
variant in an exome-sequencing dataset of a single MPD-
affected individual. However, given additional homozy-
gous rare variants and without assessment of the func-
tional consequences of this variant on protein function,
the authors were not able to categorically assign pathoge-
nicity to this variant.
Here, we report the identification of pathogenic muta-
tions in XRCC4 in multiple MPD-affected individuals,
providing definitivemolecular genetic evidence that muta-
tions in XRCC4 cause a human disease. We characterize in
detail the cellular, immunological, and phenotypic conse-
quences of these mutations, establishing that XRCC4 mu-
tations primarily result in a MPD phenotype without overt
immunodeficiency.Material and Methods
Family Ascertainment and Mutation Identification
Recruitment, exome sequencing, and variant validation were per-
formed as described previously.14 Informed consent was obtained
from all participating families, and the studies were approved the
Scottish Multicenter Research Ethics Committee (04:MRE00/19).
Parents provided written consent for the publication of photo-
graphs of the affected individuals. Z-scores (standard deviations)
were calculated by the LMS method on 1990 British Growth refer-
ence data.33 Cohort resequencing was performed by Ion AmpliSeq
multiplex PCR (Life Technologies). Primers were designed to
amplify all XRCC4 coding exons with 25 bp of flanking intronic
sequence and PCR amplification performed in1/6th reaction vol-
umes for each of three primer pools with 5 ng of human DNA. Af-The Ameter pooling of all amplicons per individual, Ion Xpress barcoding
was performed in 1/2 reaction volumes, quantified by BioAnalyser
high sensitivity chips and equal amounts of pooled amplification
products. Sequencing was performed with the Ion P1 200
Sequencing Kit on the Ion Proton sequencing platform (Life Tech-
nologies). Variants were called with Torrent Suite software. Variant
filtering was performed as per exome analysis34 and sequence
reads visually inspected by IGV.35 All variants were confirmed by
capillary sequencing; in individuals in whom a single heterozy-
gous deleterious variant was identified by NGS, the entire coding
sequence of XRCC4 was resequenced by capillary sequencing
(due to the higher false negative rate for mutation identification
around homopolymer tracts by Ion sequencing technology, to
ensure a second mutation hadn’t been misclassified in the initial
high-throughput sequencing). PCR conditions and primer se-
quences are available upon request.Construct Design and Purification
XRCC4 was amplified from pET30XRCC436 and inserted between
NcoI and BamHI sites pHAT5 vector37 to fuse a hexahistidine tag at
the C terminus of XRCC4 (pHAT5XRCC4). Plasmids expressing
XRCC4p.Trp43Arg with and without LIG4 were created from
pHAT5XRCC4 and pRSFDuet-lig4-His6-xrcc4,38 respectively, via
site-directed mutagenesis. XRCC4 and XRCC4p.Trp43Arg were puri-
fied through affinity chromatography (5 ml HisTrap HP column
[GE Healthcare]), anion-exchange chromatography (5 ml HiTrap
Q HP column [GE Healthcare]), and finally size-exclusion column
(Superdex 200 10/300 GL [GE Healthcare]). The final buffer for the
XRCC4 constructs is 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 5%
(v/v) glycerol, and 5 mM DTT. XRCC4p.Trp43Arg/LIG4 was purified
in the same manner as the wild-type.38 The SDS-PAGE gel (Fig-
ure 2C) was analyzed by mass spectrometry by Dr. Len Packman
in the PNAC facility, Department of Biochemistry, University of
Cambridge to confirm that purified proteins visualized were
LIG4 and XRCC4p.Trp43Arg.Clonogenic Survival Assay
Clonogenic survival assays with primary skin fibroblasts were per-
formed as described previously.22 LIG4 cells were derived from
F10, reported by Murray et al.14; Artemis cells are human-derived
fibroblasts from Lee et al.40 In brief, primary skin fibroblasts in
exponential growth were trypsinized, and 500–2,000 cells
(5,000–80,000 cells for the highest doses) were seeded into
10 cmplastic dishes (2 dishes per dose) and irradiated at room tem-
perature at a dose of approximately 1 Gy/min. After 12–14 days,
the cells were rinsed with 0.9% NaCl and stained with 0.25%
methylene blue for survival assessment.Immunofluorescence
Cells were seeded onto coverslips, irradiated, fixed in ice-cold 3.6%
PFA-PBS for 10 min, permeabilized in ice-cold extraction buffer
(10 mM PIPES, 20 mM NaCl, 3 mM MgCl2, 300 mM sucrose,
0.5% Triton X-100) for 5 min, and then blocked in 10% FCS for
1 hr at room temperature. Asynchronously growing cells were
stained with an anti-g-H2AX antibody (Millipore) only, whereas
G1-arrested cells were stained with an anti-g-H2AX antibody in
combination with antibody to Cyclin A (Santa Cruz Biotech-
nology). Micronuclei were detected by DAPI staining. Secondary
antibodies used were Alexa Fluor-594 goat anti-mouse IgG and
Alexa Fluor-488 goat anti-rabbit IgG (Invitrogen). Fluorescence
images were taken with a Nikon E600 Eclipse microscoperican Journal of Human Genetics 96, 412–424, March 5, 2015 413
equipped with a 603 oil lens, and images were acquired and
analyzed with Volocity Software v.4.1 (Improvision). The number
of g-H2AX foci per cell was quantified for a minimum of 500 cells
per time point. In the case of the g-H2AX foci quantification in
G1-arrested cells, g-H2AX foci were counted only in cells negative
for Cyclin A staining.
Antibodies and Western Immunoblotting
Whole-cell extracts were obtained by sonication in UTB buffer
(8 M Urea, 50 mM Tris [pH 7.5], 150 mM b-mercaptoethanol)
and centrifugation to remove insoluble debris. The following
antibodies were used: DNA-PKCS (Santa Cruz Biotechnology);
phospho-DNA-PKCS Ser-2056, DNA Ligase IV, XRCC4, and XLF
(Abcam); phospho-KAP1 Ser824 and KAP1 (Bethyl); Ku80, H2A,
and g-H2AX (Millipore), with secondary antibodies: swine anti-
rabbit IgG-HRP and goat anti-mouse IgG-HRP (Dako).
DNA DSB Labeling
All cell lines were routinely maintained as monolayers at 37C. In
DNA DSB induction/rejoining experiments, 1–2 3 106 cells were
seeded in 75 cm2 flasks 4 days prior to irradiation. 24 hr after seed-
ing, the exponentially growing cells were radioactively labeled by
media replacement with fresh, completeMEM supplemented with
0.02 mCi/ml 14C-thymidine (DuPont, 59 mCi/mmol) for 48–50 hr.
Typically, values between 0.02 and 0.08 dpmper cell were found at
the end of the labeling period.
Pulse-Field Gel Electrophoresis
Conditions used aremodified fromKysela et al.41 After 48–50hr in-
cubation, cells in stationary phase were released for a 2 hr chase
period. Cells weremixed gentlywith an equal volume of a 1% solu-
tion of low-melting-point agarose (BRL) in PBS at a final density of
2.5–3.0 3 106 cells/ml to form agarose plugs. After solidification,
plugs were irradiated in air on ice with 240 kVp X-rays at a dose
rate of 2.9 Gy/min. Immediately after irradiation, the cells were
lysed on ice with 3 volumes of lysis solution (0.5 M EDTA, 1% N-
lauroylsarcosine, 1 mg/ml proteinase K) and incubating at 50 for
40 hr. In order to investigate DNADSB repair, the irradiated inserts
(together with unirradiated controls) were placed into 7 ml of pre-
warmed completeMEM in culture dishes, incubated under normal
growth conditions for various time intervals, and then lysed as
described above. After lysis, DNA samples in agarose inserts were
extensively washed 5 times against 100 volumes of TE buffer to
avoid any remaining proteinase K and detergent contamination.
Agarose gels (0.8%, BRL ultraPURE) were cast in 0.53 TBE buffer
(13 TBE: 90 mM Tris base, 90 mM boric acid, and 2.5 mM EDTA).
Electrophoresis conditions used were: initial switching time,
30min; final switching time, 30min; running time, 48 hr; voltage,
1.5V/cm; angle, 120; temperature, 14C; on a CHEF-DR III appa-
ratus (BIORAD). Gels were analyzedwith STORMPhosphorimager.
IGH Repertoire Analysis
VH-JH junctions were amplified from peripheral blood mononu-
clear cells in a multiplex PCR with the VH1-6 FR1 and JH
consensus BIOMED-2 primers.42 The primers were adapted for
454 sequencing by adding the forward A or reverse B adaptor,
the ‘‘TCAG’’ key, and multiplex identifier (MID) adaptor. PCR
products were purified by gel extraction (QIAGEN) and Agencourt
AMPure XP beads (Beckman Coulter). Subsequently, the PCR con-
centration was measured with the Quant-it Picogreen dsDNA
assay (Invitrogen). The purified PCR products were sequenced on414 The American Journal of Human Genetics 96, 412–424, March 5the 454 GS junior instrument according the manufacturer’s
recommendations, using the GS junior Titanium emPCR kit
(Lib-A), sequencing kit, and PicoTiterPlate kit (454 Life Sciences,
Roche). Using the CLC genomic workbench software, the samples
were separated based on their MID sequence and trimmed and
reads with a quality score below 0.05 and below 250 bp were dis-
carded. The reads were uploaded to IMGT HighV-Quest.43 Subse-
quently these output files were uploaded to the custom Galaxy
platform.44–46 Further processing was done in the ‘R’ programing
language47 to generate the tabular outputs.
In Vitro V(D)J Recombination
XR1 cells (XRCC4-deficient Chinese hamster ovary cells) were
transfected with a recombination substrate (pDVG93) containing
two recombination signal sequences (RSS) in inverted orientation,
RAG1 and RAG2 expression constructs, and pCDNA containing
either WT or XRCC4 mutation expression constructs. After
48 hr, the cells were harvested and extrachromosomal DNA was
isolated. Upon recombination, the sequence between the two
RSS is inverted, which could be detected by qRT-PCR. The level
of recombination activity of wild-type XRCC4 was set at 100%.Results
Identification of XRCC4 Mutations in Six
MPD-Affected Individuals
After our recent report of LIG4 mutations in 11 individ-
uals,14 we identified further compound heterozygous mu-
tations in LIG4 by exome sequencing in dizygotic twins
with MPD (Table S1). In addition to the common previ-
ously reported p.Arg814* termination, the two siblings
were compound heterozygous for the missense mutation
c.2321T>C (p.Leu774Pro) (RefSeq accession number
NM_002312.3). Leu774 lies within the XRCC4 binding
motif and is conserved between humans and yeasts
(Figure S1). The location of the substitution led us to hy-
pothesize that the interaction between LIG4 and XRCC4
might be of particular relevance to the growth phenotype.
Additionally, analysis of exome sequencing for rare,
deleterious recessive variants in a large cohort of MPD-
affected individuals identified a homozygous missense
variant in XRCC4 in a Saudi Arabian individual (P1) with
extreme microcephaly (8.3 SD) and short stature
(4.7 SD). This mutation, c.127T>C (p.Trp43Arg) (RefSeq
NM_022550.2), was confirmed by capillary sequencing
and segregated appropriately within the family. The
allele frequency for this variant was 3.3 3 105 in control
populations, with no homozygotes reported (ExAC
Consortium). The deleterious prediction by SnpEff48 in
combination with the rare allele frequency suggested
that mutations in XRCC4 represent a previously uncharac-
terized cause of MPD.
Given these two lines of evidence, the entire coding re-
gion of XRCC4 was resequenced in our cohort of MPD-
affected individuals (n ¼ 208) via AmpliSeq multiplex
PCR/Ion Proton NGS sequencing. This resulted in identifi-
cation of five additional individuals from four families
with biallelic mutations in XRCC4 (Table 1, Figure 1). All, 2015
Table 1. Mutations in XRCC4 in MPD-Affected Individuals
Pt Nucleotide Mutations Amino Acid Alterations Sex Country of Origin
P1 c.127T>C (homozygous) p.Trp43Arg M Saudi Arabia
P2 c.481C>T þ c.673C>T p.Arg161* þ p.Arg225* M Morocco
P3-1 c.25delC þ c.823C>T p.His9Thrfs*8 þ p.Arg275* M Italy
P3-2 c.25delC þ c.823C>T p.His9Thrfs*8 þ p.Arg275* M Italy
P4 c.25delC þ c.823C>T p.His9Thrfs*8 þ p.Arg275* M France
P5 c.25delC þ c.101G>T p.His9Thrfs*8 þ (splicing) M UK
RefSeq NM_022550.2. All parents were sequenced and mutations segregated appropriately.mutations identified were validated by capillary se-
quencing in affected individuals, and segregation was
confirmed in parents.
Individuals with XRCC4 Mutations Exhibit Severe
Pre- and Postnatal Growth Failure
Growth measurements in all individuals (Figure 1A, Ta-
ble 2) demonstrated significant reduction in both head
and body size at birth (median OFC 3.59 5 1.19 SD;
length4.945 1.75 SD; weight3.145 0.64 SD). Postna-
tally, affected individuals developed extrememicrocephaly
(median 8.15 5 1.93 SD) along with significant reduc-
tion in height (4.65 2.02 SD), similar to those we previ-
ously reported for individuals with LIG4 mutations.14
Additionally, individuals with XRCC4-MPD exhibited
facial similarities, including fine sparse hair, small chin,
and broad nasal tip (Figure 1B). Developmental delay was
present in only some, and no recurrent developmental
malformations were apparent. No malignancies were re-
ported and, importantly, there was no clinical suspicion
of immunodeficiency in these individuals.
XRCC4 Mutations Markedly Reduce Cellular Levels
of XRCC4 and LIG4
We predicted that prematurely truncating XRCC4 muta-
tions were likely to be functionally deleterious by reducing
protein levels via nonsense-mediated decay (Figure 2A).
For the substitution p.Trp43Arg, its conservation in verte-
brates suggests that it would also substantially impact
function (Figure 2B). Furthermore, structural analysis sug-
gested that substitution of this hydrophic residue (Trp43)
with a positively charged arginine would lead to the desta-
bilization of the XRCC4 head domain. Trp43 is a part of a
hydrophobic core formed by Leu36, Asp38, Ser41, Phe88,
Lys90, Leu113, and Lys115 (Figure 2C), and the substitu-
tion to arginine was predicted to cause a distortion of
two layers of b sheets, disrupting the buried hydrophobic
core, as well as affecting the helix-turn-helix motif in the
head domain of XRCC4. Additionally, structure-based
computational analysis of the p.Trp43Arg substitution
via DUET49 indicated that the substitution destabilizes
the structure of XRCC4.
To address these structural predictions, we expressed and
purified recombinant XRCC4WT and XRCC4p.Trp43Arg fromThe AmeE. coli. Significantly, in contrast to wild-type XRCC4, the
p.Trp43Arg substitution greatly reduced protein solubility,
with the majority of the full-length protein residing in
insoluble fractions of the bacterial extract. Despite this,
we were able to purify some full-length XRCC4p.Trp43Arg
protein. However, this was more prone to degradation
(Figure 2D), either when expressed by itself or in combina-
tion with LIG4. Furthermore, although the circular dichro-
ism (CD) spectrum of the XRCC4p.Trp43Arg form indicated
that the protein is folded, it differed from wild-type
(Figure S2). Nevertheless, because in vitro ligation assays
using XRCC4p.Trp43Arg recombinant protein in conjunc-
tion with either blunt or cohesive DNA ends did not detect
any significant reduction in ligation efficiency (Figure S3),
we concluded that the p.Trp43Arg substitution more
likely affects protein stability rather than directly affecting
XRCC4 function.
Because human-derived primary fibroblasts containing
the p.Trp43Arg substitution were available from P1, we
next performed immunoblotting to assess cellular levels
of NHEJ components (Figure 2E). Protein levels of
XRCC4 were strongly reduced in P1 cells, in keeping
with our biochemical analysis. Furthermore, XLF and
particularly LIG4, which form a complex with XRCC4,
were also reduced, indicating that the reduction in
XRCC4 affects stability of this whole complex. Likewise,
a similar decrease of XRCC4/LIG4/XLF was also seen in
LIG4 human cells (derived from F10, reported in Murray
et al.14). Other components of the NHEJ machinery
(Ku80 and DNA-PKCS) were not decreased in either LIG4
or XRCC4 cells, in keeping with their role upstream of
the XRCC4/LIG4/XLF complex.
Primary fibroblasts were also available from indivi-
dual P5. Here an early truncating mutation was present
(c.25delC [p.His9Thrfs8*]) in conjunction with an essen-
tial splice acceptor mutation in exon 2 (c.101G>T).
RT-PCR identified an aberrant splicing product (Figure S4)
that results in loss of exon 2 (containing the translation
initiation codon) from a proportion of transcripts. This,
in conjunction with the early truncating mutation, would
be expected to lead to marked reduction in protein levels,
and indeed immunoblotting of protein extracts from P5 fi-
broblasts detected markedly reduced XRCC4 (and LIG4)
levels (Figure 2E).rican Journal of Human Genetics 96, 412–424, March 5, 2015 415
A B Figure 1. Mutations in XRCC4 Result in
Prenatal-Onset Growth Failure with
Disproportionate Microcephaly
(A) Growth is delayed both pre- and
post-natally; individuals with XRCC4 al-
terations (black) have similar growth pa-
rameters to those seen in individuals with
LIG4 alterations (gray).14 Data plotted for
six individuals with biallelic missense or
truncating mutations in XRCC4. Mean 5
SD. Abbreviations are as follows: OFC, oc-
cipital-frontal circumference; Wgt, weight;
Lgt, length; Hgt, height.
(B) Facial features of individuals with mu-
tations in XRCC4. P2 aged 11 months
(left) and 4 years (right); P5 aged 5 months
(left) and 21 months (right).From these cellular studies, we concluded that XRCC4
mutations lead to substantial loss of both XRCC4 and
LIG4 from cells, which would be predicted to result in a
significantly reduced activity of the ligase IV complex, im-
pairing NHEJ. We therefore next examined NHEJ activity
in these cells.
Cells with XRCC4 Mutations Have Elevated
Sensitivity to Ionizing Radiation due to
Impaired NHEJ
NHEJ-deficient cells have increased sensitivity to ionizing
radiation (IR).27 Therefore, we assessed XRCC4 fibroblast
viability after IR in a clonogenic survival assay. After irradi-
ation, XRCC4-mutated cells exhibited impaired survival
(Figure 3A) with hypersensitivity to IR comparable to cells
from published Artemis- and LIG4-altered individuals.13,50
To further characterize the cellular response to IR in
these cells in more detail, we monitored the resolution of
g-H2AX foci by immunofluorescence as a measure of their
capacity to repair DSBs. After irradiation, equal numbers of
foci were detected in XRCC4 and control cells; however, at
24 hr after irradiation, 99.4% of P1 and 62.3% of P5 asyn-
chronous cells had>5 g-H2AX foci compared to 9.2% con-
trol cells (p < 0.0001), indicating that XRCC4 (and LIG4)
mutations disrupted the ability of the cell to resolve DNA
damage induced by IR (Figure 3B). To confirm that this
was the consequence of defective NHEJ, cells were syn-
chronized in G1 by contact inhibition and followed over
a time course of 24 hr to examine the kinetics of DSB repair
(Figures S5 and S6). XRCC4 fibroblasts again failed to
resolve DNA breaks at 24 hr after IR (p < 0.001) (Figures
3Bii and S6). This observation was confirmed by immuno-
blotting, which also showed persistent activation of the
DNA damage response in these cells in response to low-
dose gamma radiation (Figure 3E). This is suggestive of
defective NHEJ, because homologous recombination is416 The American Journal of Human Genetics 96, 412–424, March 5, 2015not active in this cell cycle stage.
Consistent with this, pre-treatment
of the human-derived fibroblasts
with a DNA-PK inhibitor prior to irra-diation did not exacerbate the defect in resolving g-H2AX
foci (Figure S5).
To investigate DSB repair kinetics in cells more directly,
we performed pulse-field gel electrophoresis (PFGE) (Fig-
ure 3C). After irradiation, the initial levels of DSBs were
comparable between XRCC4-mutated and control cells
(Figure 3Ci). However, over a 24 hr time course, almost
95% of DNA breaks detected by PFGE were resolved in con-
trol cells compared to only 42% of XRCC4-mutated cells
(p ¼ 4 3 108, t test, n ¼ 5 experiments). In keeping with
this, we observed increased numbers of micronuclei in
XRCC4-mutated cells, most likely due to a failure to repair
DSBs (Figure 3D, p < 0.05, ANOVA, n ¼ 3 experiments).
We therefore concluded that XRCC4 mutations lead to
significant impairment of DSB break repair in cells.
Clinical Immunological Parameters Are Normal
in Most Individuals with XRCC4 Mutations
No increased susceptibility to infection was reported by
clinicians caring for XRCC4-MPD-affected individuals.
However, given the immunodeficiency documented in
individuals with mutations in other NHEJ genes,40 due to
either T/B cell depletion as the consequence of failed
V(D)J recombination or progressive pancytopenia and
bone marrow failure in LIG4-MPD-affected individ-
uals,13,14 we performed detailed immunological and hema-
tological investigations.
Strikingly, for the majority of individuals, there was no
evidence of immunodeficiency or bone marrow failure,
with blood cell counts, T cell and B cell subsets, and immu-
noglobulin (Ig) levels all within the normal ranges (Table 3).
An isolated lymphopenia was evident in P1, affecting all
T cell and B cell subsets, and a borderline leukopenia was
recorded in P3-1, without deficits in T/B cell subsets. For
P1 (with the p.Trp43Arg substitution), the reduction in
lymphocyte number was chronic and nonprogressive on
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The Amerepeated measurements, with lymphocyte count being
20% of mean reference range at 3 and 6 years (Table S3).
Further, extended assessment of T cell and B cell subsets
was performed on three of the individuals by FACS
(Table S2). Normal values were demonstrated for all subsets
analyzed in P3-1 and P3-2; and for P1, naive, effector, and
central/memory B cell and T cell subsets were all present,
albeit at reduced levels. Additionally, levels of IgG and IgA
werewithin the normal range for P1, indicating that despite
class switching being dependent on NHEJ, XRCC4 defi-
ciencyhasnothampered switching from IgM. Furthermore,
P1 demonstrated normal responses to vaccines (Table S4).
We therefore concluded that our XRCC4 cohort had
functional immune systems. Depletion of lymphocytes
in P1 could be accounted for by impaired V(D)J recombina-
tion depleting T/B cell pools, so we next examined XRCC4
deficiency on V(D)J recombination at a molecular level.
Immune Receptor Junction Diversity Is Perturbed
in Individuals with XRCC4 Mutations
To assess the molecular impact of XRCC4 deficiency on
V(D)J recombination, we undertook deep sequencing across
V(D)J junctions from peripheral blood lymphocytes. By us-
ing 454 sequencing, we defined the repertoire of functional
IGH gene rearrangements in both control and XRCC4 cells,
quantifying the number of unique junction sequences
generated, as well as characteristics such as nucleotide dele-
tions, random non-templated nucleotide (N) insertions,
and palindromic (P) nucleotides caused by asymmetric
hairpin opening (Figure 4). Substantial junctional diversity
was present in XRCC4 cells, with large numbers of unique
productive IGH sequences being detected, and in keeping
with adequate functioning of adaptive immunity in these
individuals. Furthermore, there were no quantitative differ-
ences in nucleotide deletions or palindromic nucleotides
from controls. However, there were significant reductions
in the total number of random nucleotides inserted in
V(D)J junctions of individuals with XRCC4 mutations
(p < 0.008). Given that nucleotide insertion is performed
by the DNA polymerase TdT and in vitro the action
of TdT is mediated by NHEJ components Ku80 and
XRCC4,51 this therefore provided in vivo validation for
the role of XRCC4 in this aspect of V(D)J recombination.
Finally, we comprehensively assessed the effect of all
the mutations identified on V(D)J recombination in an
in vitro overexpression recombination assay (Figure 4B).
As expected from our cellular studies, the point substitu-
tion p.Trp43Arg resulted in impaired, but not completely
abrogated, V(D)J recombination (p¼ 0.004, t test). All other
individuals were compound heterozygous for two trun-
cating mutations; for every individual at least one segre-
gating mutation (encoding p.Arg275* or p.Arg225*) had
residual functionality in this assay. Hence, although these
mutations are prematurely truncating and therefore sub-
jected to nonsense-mediated decay, a small fraction might
escape, producing truncated protein that is functional for
V(D)J recombination within the cells. The embryonicrican Journal of Human Genetics 96, 412–424, March 5, 2015 417
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Figure 2. XRCC4 Mutations Markedly Reduce Levels of Both LIG4 and XRCC4 Proteins
(A) Schematic of XRCC4 indicating protein domains, the LIG4 interaction region, and locations of mutations identified. Head domain,
blue; coiled-coiled domain, orange; C-terminal domain, gray.
(B–D) The p.Trp43Arg substitution destabilizes the head domain, significantly reducing XRCC4 stability and solubility.
(B) The tryptophan residue at codon 43 is conserved in all vertebrates. NCBI RefSeq sequences aligned with ClustalOmega.
(C) Trp43 (W43) along with Leu36, Asp38, Ser41, Peh88, Lys90, Leu113, and Lys115 form the hydrophobic core of the head domain of
XRCC4. The arginine substitution for tryptophan at codon 43 is likely to distort two layers of b sheets, disrupting the buried hydropho-
bic core, resulting in exposure of hydrophobic residues to solvent and leading to insolubility, aggregation, and structure destabilization.
Left, a magnified view of the head domain containing Trp43. Right, the XRCC4 dimer (silver and gold) in complex with a fragment of
LIG4 (cyan) (PDB code 1IK939).
(D) Generation of recombinant XRCC4p.Trp43Arg is substantially less efficient than XRCC4WT protein. Yield of recombinant
XRCC4p.Trp3Arg is also reduced even when expressed with its constitutive heterodimer partner LIG4. SDS-PAGE of recombinant LIG4,
XRCC4WT, and XRCC4p.Trp43Arg, after purification with additional lower-molecular-weight bands consistent with reduced protein stabil-
ity. Column labeled ‘‘M’’ indicates protein size standards. In contrast to XRCC4WT protein, the majority of XRCC4p.Trp43Arg is insoluble
(data not shown).
(E) Both missense and truncating mutations in XRCC4markedly reduce both XRCC4 and LIG4 protein levels. Immunoblotting of NHEJ
components in control, LIG4, and XRCC4 cells demonstrates that XRCC4 protein is detectable in P1- and P5-derived fibroblasts only
after prolonged immunoblot exposure. Because XRCC4 and LIG4 form a stable heterodimer, there is consequential reduction in
LIG4 protein levels.lethality of the mouse Xrcc4/ model52 supports our
conclusion from this and our cellular analyses, that the
XRCC4 mutations represent severe hypomorphic alleles.Discussion
Our recent description of mutations in LIG4 as a common
cause of MPD prompted us to investigate the relevance of
other NHEJ components for the etiology of MPD. Through418 The American Journal of Human Genetics 96, 412–424, March 5exome sequencing and next-generation resequencing we
have identified six individuals with biallelic mutations in
XRCC4. We provide comprehensive biochemical, cellular,
and immunological analysis to support the pathogenicity
of these mutations. In doing so, we also provide functional
evidence confirming the deleterious nature of a previously
proposed potential pathogenic variant (p.Trp43Arg),32
which is identical to the mutation we identified in P1.
Notably, both individuals, though apparently unrelated,
are from Saudi Arabia and therefore the nucleotide, 2015
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Figure 3. XRCC4 Cells Are Hypersensitive to Ionizing Radiation due to Impaired NHEJ
(A) XRCC4 cells exhibit hypersensitivity to ionizing radiation, similar to LIG4- and Artemis-altered individuals. Clonogenic survival as-
says performed on primary fibroblasts. Survival at 12–14 days after exposure to ionizing radiation, at doses as indicated. n ¼ 2 experi-
ments. Mean5 SD.
(B) Significantly elevated levels of g-H2AX foci (a marker of double-strand break formation) are present 24 hr after irradiation in XRCC4
fibroblasts, both in asynchronous (exposed to 3 Gy IR) and G1-arrested cells (exposed to 2 Gy IR). (Bi) Representative immunofluores-
cence images. Red, g-H2AX. (Bii) Quantification of g-H2AX foci. n ¼ 3 experiments. Mean5 SEM. Statistical test: ANOVA. For detailed
quantification and time course, see Figures S5 and S6.
(C) Pulse-field gel electrophoresis also demonstrates impaired double-strand DNA break (DSB) resolution in XRCC4 cells after 2.9 Gy IR.
Although ionizing radiation results in comparable levels of DSBs in both control and P1 fibroblasts (XRCC4Trp43Arg) (Ci), the subsequent
kinetics of DSB repair are markedly impaired (Cii). Whereas control cells are able to resolve the majority of breaks within 24 hr, 58%5
6.0% of breaks remain unresolved in XRCC4p.Trp43Arg cells, compared to 5.4%5 2.6% in control cells. n ¼ 5 experiments, mean5 SD.
(D)Micronuclei, as indicator of genome instability, was quantified in cells 24 hr after 3 Gy IR. n¼ 3 experiments, mean5 SEM. Statistical
test: ANOVA.
(E) DNA damage response is prolonged in XRCC4 fibroblasts. Immunoblotting of protein extracts from fibroblast cell lines previously
synchronized in G1 (to enrich for NHEJ-mediated repair) at time points indicated after 2 Gy IR. Cellular DNA damage response examined
by assessing levels of activated H2A (g-H2AX) and Ser824 phosphorylation of KAP1. The level of NHEJ activity was measured with phos-
phorylated DNA-PKCS. H2A and KAP1 serve as loading controls.
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420 The American Journal of Human Genetics 96, 412–424, March 5substitution probably represents a founder mutation in this
population.
All XRCC4-MPD-affected individuals demonstrated in
utero and postnatal growth retardation similar to that
seen in LIG4-MPD-affected individuals.14 Microcephaly
was present at birth, becoming more evident postnatally.
This disproportionate extreme microcephaly suggests
that neurogenesis might be particularly sensitive to DNA
damage in these individuals, similar to mutations in
several other NHEJ genes.27 Increased apoptosis, reported
in the Xrcc4/ mouse,52 might therefore deplete cell
numbers during development, explaining severe reduction
in both head size and body size. Failure to resolve DSBs in a
timelymanner could also slow proliferation, reducing total
cell number.
XRCC4 cells exhibit a marked sensitivity to ionizing ra-
diation and therefore clinical exposure to X-rays should
be minimized. Although no tumors or hematological ma-
lignancy have been observed, our cohort is relatively
young in age and given their cellular sensitivity to ionizing
radiation and the reports of cancer associated with other
NHEJ genes,53 risks are probably elevated in these individ-
uals. Surprisingly, immune function is preserved in our
cohort, despite the key role NHEJ plays in V(D)J recombi-
nation to generate adaptive immune cell diversity.
Notably, at the molecular level, deficits in specific aspects
of recombination are evident, particularly in TdT-depen-
dent random nucleotide insertion. Significantly, this
observation provides in vivo validation for previous work
demonstrating the role of XRCC4 in recruitment of TdT
during V(D)J recombination.51
Despite encoding components of a protein complex,36
LIG4- and XRCC4-mutated individuals might have pheno-
typic differences. Individuals with LIG4mutations develop
pancytopenia, caused by progressive depletion of the he-
matopoietic stem cell pool.54 In contrast, XRCC4-mutated
individuals of a similar age do not demonstrate pancyto-
penia, suggesting a potential differential requirement for
stem cell maintenance. Nevertheless, hematological moni-
toring of XRCC4-mutated individuals should continue
because pancytopenia could develop in later childhood.
The identification of older individuals would also help
address this specific issue. Furthermore, resequencing of
XRCC4 in individuals with RS-SCID and other cohorts
will be important to define the full spectrum of pheno-
types associated with mutations in this gene.
Severe growth failure without symptomatic immunode-
ficiency in many LIG4- and XRCC4-mutated individuals
suggests a phenotype spectrum among individuals with
NHEJ mutations (Figure S7). At one end, mutations cause
extreme growth failure and microcephaly, whereas con-
versely, mutations in DCLRE1C (encoding Artemis) cause
RS-SCID (radiosensitive severe combined immunode-
ficiency) without microcephaly or short stature.27 With
NHEJ1 (encoding XLF) mutations, RS-SCID is typically
seen in conjunction with marked microcephaly and
growth failure (MIM 611291).30, 2015
AB
Figure 4. XRCC4 Mutations Do Not
Significantly Impact V(D)J Recombination
(A) Next-generation sequencing of the re-
combined IgH locus demonstrates that
XRCC4 lymphocytes contain a large num-
ber of unique V(D)J recombination events.
Upper panel, summary of V(D)J junction
characteristics following 454 deep se-
quencing and analysis using the IGGalaxy
antigen receptor tool. Lower panel, a sig-
nificant decrease in insertional events is
detected at V(D)J junctions (p ¼ 0.0008; t
test), providing in vivo confirmation for
XRCC4’s role in recruiting terminal deoxy-
nucleotide transferase to immunoglobulin
V(D)J junctions, which adds additional
nucleotides during recombination. Mean
5 SD.
(B) Missense and some truncated forms of
XRCC4 retain reduced competence for
V(D)J recombination. Plasmids of XRCC4
cDNA with mutations (as indicated) were
overexpressed in an XRCC4-deficient cell
line and recombination activity assayed
by qRT-PCR. Efficiency is expressed as
percentage of wild-type activity. n ¼ 4 ex-
periments, error bars ¼ SEM. *p < 0.05;
***p < 0.001; ****p < 0.0001.Such variation in phenotypes between individuals with
mutations in NHEJ genes poses an important question as
to the respective role of the proteins they encode in adap-
tive immunity, neurogenesis, and general growth. XRCC4
mutations are likely to result in a global reduction in effi-
ciency of NHEJ repair during development, explaining
reduced body size and microcephaly. Residual ligase com-
plex activity in these individuals could, however, explain
the absence of SCID phenotype, because positive selection
of cells possessing functional T cell receptors and immuno-
globulins during adaptive immune cell maturation might
be able to compensate for impaired V(D)J recombination
efficiency. In contrast, null mutations inDCLRE1C (encod-
ing Artemis) cause RS-SCID with no microcephaly or
growth deficit (MIM 602450),27 because only a subset of
DSBs arising from DNA damage require Artemis55 and
therefore NHEJ repair during development might be suffi-
cient for normal growth. However, in order for V(D)J
recombination to succeed, additional end-processing by
Artemis is essential to cleave hairpin structures formed af-The American Journal of Humanter the actions of RAG1/2.56 Failure to
perform this cleavage consequently
causes the RS-SCID phenotype.
Althoughmicrocephaly and growth
failure in both LIG4- and XLF-
mutated individuals might be attrib-
uted to their core role in NHEJ liga-
tion, why XLF, in contrast to LIG4
and XRCC4, has invariably been
associated with SCID is less easy to
explain. Likewise, gene-phenotype
correlations are complicated by strik-ing variation between individuals with mutations in
PRKDC (encoding DNA-PKCS [MIM 615966]) and also in
LIG4.22,28,29 Additional complexities in NHEJmechanisms,
including regulatory phosphorylation by DNA-PKCS on
multiple components,57 functional redundancy,58 and
alternative cellular pathways59 might help account for
these differences.
In summary, we present comprehensive genetic and
cellular evidence that mutations in XRCC4 cause microce-
phalic primordial dwarfism. The absence of an overt clin-
ical immunodeficiency highlights differing requirements
for NHEJ genes during growth, neurogenesis, and genera-
tion of the adaptive immune repertoire, demonstrating
the complexity of this important cellular pathway.Supplemental Data
Supplemental Data include seven figures and four tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2015.01.013.Genetics 96, 412–424, March 5, 2015 421
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